- Home
- / Verve Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Verve Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$6
2024-10-29
Market Capitalization
$506.9 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|
| General and administrative expense | 18.9M | 37.5M | 49.9M | 56.6M |
| Operating expense total | 167.6M | 234.9M | 261.0M | |
| EBIT | (87.1M) | (165.7M) | (223.1M) | (228.7M) |
| Pre tax profit | 120.3M | (157.3M) | (199.8M) | (198.4M) |
| Income tax expense | 53.0K | 275.0K | 349.0K | |
| Net Income | (120.3M) | (157.4M) | (200.1M) | (198.7M) |
| EPS | (2.9) | (3.1) | (2.3) |